EPHA4, His, Human
EPHA4, His, Human

The purity of EPHA4, His, Human is greater than 95% as determined by SEC-HPLC.

EPHA4, His, Human

EPHA4, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

EPHA4, His, Human

The expression and activation of EphA4 in the various cell types in a knee joint was upregulated upon an intraarticular injury. To determine if EphA4 signaling plays a role in osteoarthritis, we determined whether deficient EphA4 expression (in EphA4 knockout mice) or upregulation of the EphA4 signaling (with the EfnA4-fc treatment) would alter cellular functions of synoviocytes and articular chondrocytes. In synoviocytes, deficient EphA4 expression enhanced, whereas activation of the EphA4 signaling reduced, expression and secretion of key inflammatory cytokines and matrix metalloproteases.
Z05251
¥63,425.00

Ask us a question
Product Introduction
Species Human
Protein Construction
EPHA4 (Val20-Thr547)
Accession # P54764-1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 59.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-70 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • EPHA4, His, Human
    • EPHA4, His, Human

    The purity of EPHA4, His, Human is greater than 95% as determined by SEC-HPLC.

  • EPHA4, His, Human
    • EPHA4, His, Human

    EPHA4, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background The expression and activation of EphA4 in the various cell types in a knee joint was upregulated upon an intraarticular injury. To determine if EphA4 signaling plays a role in osteoarthritis, we determined whether deficient EphA4 expression (in EphA4 knockout mice) or upregulation of the EphA4 signaling (with the EfnA4-fc treatment) would alter cellular functions of synoviocytes and articular chondrocytes. In synoviocytes, deficient EphA4 expression enhanced, whereas activation of the EphA4 signaling reduced, expression and secretion of key inflammatory cytokines and matrix metalloproteases.
Synonyms Sek; Sek1; EphA4; HEK8; SEK; TYRO1; EK8

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.